Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00201123 · ClinicalTrials.gov registry record · Phase 2
Effects of Interferon-Gamma on Cavitary Pulmonary Tuberculosis in the Lungs
A Phase 2 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 89
- Enrollment target
NCT00201123: Completed Phase 2 study, sponsored by NYU Langone Health.
NCT00201123 is a Phase 2 study that has completed, run by NYU Langone Health. The registered enrollment target is 89 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (33% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00201123, a Phase 2 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 89 participants
- Enrollment target
Study Summary
This study will evaluate the lung's immune response to mycobacterium tuberculosis (Mtb) infection and will modulate that response with interferon-gamma.
Interventions
- OTHER Placebo
- DRUG Aerosol Interferon-Gamma
- DRUG Subcutaneous interferon-gamma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2005-04 |
| Est. Completion | 2007-08 |
| Phase | Phase 2 |
What the finished NCT00201123 record still lists
NCT00201123 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 89 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (33% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00201123 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00201123 about?
NCT00201123 is a clinical study titled "Effects of Interferon-Gamma on Cavitary Pulmonary Tuberculosis in the Lungs". This study will evaluate the lung's immune response to mycobacterium tuberculosis (Mtb) infection and will modulate that response with interferon-gamma.
What is the current status of trial NCT00201123?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 89 participants. The study started on 2005-04. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00201123?
The interventions under investigation include: Placebo (OTHER), Aerosol Interferon-Gamma (DRUG), Subcutaneous interferon-gamma (DRUG).
Who is sponsoring clinical trial NCT00201123?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00201123's enrollment target sits among peer trials
89 802nd of 2000 higher than 1,198 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03682289 · 89 participants · Phase 2
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
- NCT04787939 · 89 participants · NA
Early Feeding After Oral Cavity Reconstruction
- NCT05480449 · 89 participants · Phase 1
Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)
- NCT05604131 · 89 participants · Phase 2
Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia